| Description | This product is a monoclonal antibody derived from Human (Homo sapiens), which can specifically recognize Fibroblast growth factor receptor 4. The antibody is expressed with mammalian cell transient expression system, serum-free and purified by affinity chromatography. The purity and integrity are tested via SDS-PAGE and SEC-HPLC analysis. Given an antigen, additional QC measures are also desired such as affinity testing and binding validation. Specifically, the antibody is provided in multiple formats for in vivo and in vitro assays. The Invivo version features greater than 95% purity, ultra-low endotoxin levels (<1 EU/mg or 0.1 EU/mg), and is preservative, stabilizer, and carrier protein-free. |
| Clonality | Monoclonal |
| Host Species | Human |
| Target Species | Human |
| Isotype | IgG |
| Expression Species | HEK293F or CHO |
| Conjugation | None |
| Purity | >95%, determined by SDS-PAGE and/or SEC-HPLC |
| Endotoxin | <1 EU/mg, determined by LAL method |
| Purification | Protein A affinity purified |
| Sterility | 0.2 μM filtered |
| Formulation | PBS, pH 7.4 |
| Preservation | No preservatives |
| Stabilizer | No stabilizers |
| Storage | Store at 4⁰C within a week. For longer storage, aliquot and store at -20⁰C. |
| Application | ELISA |
| Application Notes | The antibody is recommended for detection of FGFR4 by ELISA assay. |
| ELISA | Enzyme-Linked Immunosorbent Assay Protocol |
| WB | Western Blot Protocol |
| FC | Flow Cytometry Protocol |
| Target | FGFR4 |
| Alternative Name | FGFR4; fibroblast growth factor receptor 4; TKF; JTK2; CD334; tyrosylprotein kinase; protein-tyrosine kinase; hydroxyaryl-protein kinase; tyrosine kinase related to fibroblast growth factor receptor |
| Gene ID | 2264 |
| UniProt | P22455 |
| Research Area | Cardiovascular |
| Related Disease | Liver cancer, solid tumors |
Figure 1 Anti-Human FGFR4 Antibody (V3S-0522-YC1393) in ELISA.
ELISA analysis of V3S-0522-YC1393 was performed by coating with FGFR4 protein, human, recombinant (His Tag).
Incubation: Antigen, 1 µg/mL, 100 µl/well
The secondary antibody: HRP-anti-human IgG (H+L)
Figure 1 Anti-Human FGFR4 Antibody (V3S-0522-YC1393) in ELISA.
Figure 2 Anti-Human FGFR4 Antibody (V3S-0522-YC1393) in Western Blot.
Western blot analysis of V3S-0522-YC1393 was performed by loading FGFR4 protein, human, recombinant (His Tag).
V3S-0522-YC1393 incubation concentration: 2 ng/μL.
The secondary antibody: HRP-anti-human IgG (H+L)
Left: Reduced antigen (0.1 μg, 0.3 μg, 0.6 μg)
Right: Non-Reduced antigen (0.1 μg, 0.3 μg, 0.6 μg)
Figure 2 Anti-Human FGFR4 Antibody (V3S-0522-YC1393) in Western Blot.
Figure 3 Anti-Human FGFR4 Antibody (V3S-0522-YC1393) in Dot Blot.
Dot blot analysis of V3S-0522-YC1393 was performed by coating with FGFR4 protein, human, recombinant (His Tag).
V3S-0522-YC1393 incubation concentration: 2 ng/μL.
The secondary antibody: HRP-anti-human IgG (H+L)
Figure 3 Anti-Human FGFR4 Antibody (V3S-0522-YC1393) in Dot Blot.
